WO2005115452A3 - Fcϝriib-specific antibodies and methods of use thereof - Google Patents

Fcϝriib-specific antibodies and methods of use thereof Download PDF

Info

Publication number
WO2005115452A3
WO2005115452A3 PCT/US2005/012798 US2005012798W WO2005115452A3 WO 2005115452 A3 WO2005115452 A3 WO 2005115452A3 US 2005012798 W US2005012798 W US 2005012798W WO 2005115452 A3 WO2005115452 A3 WO 2005115452A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
fcϝriib
fcϝriia
fragments
administering
Prior art date
Application number
PCT/US2005/012798
Other languages
French (fr)
Other versions
WO2005115452A9 (en
WO2005115452A2 (en
Inventor
Scott Koenig
Maria Concetta Veri
Nadine Tuaillon
Ezio Bonvini
Jeffrey Stavenhagen
Christopher Rankin
Original Assignee
Macrogenics Inc
Scott Koenig
Maria Concetta Veri
Nadine Tuaillon
Ezio Bonvini
Jeffrey Stavenhagen
Christopher Rankin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc, Scott Koenig, Maria Concetta Veri, Nadine Tuaillon, Ezio Bonvini, Jeffrey Stavenhagen, Christopher Rankin filed Critical Macrogenics Inc
Priority to JP2007508555A priority Critical patent/JP5367982B2/en
Priority to AU2005247301A priority patent/AU2005247301B2/en
Priority to MXPA06011796A priority patent/MXPA06011796A/en
Priority to CA002563314A priority patent/CA2563314A1/en
Priority to EP05778285A priority patent/EP1747237A4/en
Publication of WO2005115452A2 publication Critical patent/WO2005115452A2/en
Publication of WO2005115452A9 publication Critical patent/WO2005115452A9/en
Publication of WO2005115452A3 publication Critical patent/WO2005115452A3/en
Priority to IL178593A priority patent/IL178593A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention relates to antibodies or fragments thereof that specifically bind FcϜRIIB, particularly human FcϜRIIB, with greater affinity than said antibodies or fragments thereof bind FcϜRIIA, particularly human FcϜRIIA. The present invention also provides the use of an anti-FcϜRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
PCT/US2005/012798 2004-04-16 2005-04-15 Fcϝriib-specific antibodies and methods of use thereof WO2005115452A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2007508555A JP5367982B2 (en) 2004-04-16 2005-04-15 FcγRIIB specific antibody and method of use thereof
AU2005247301A AU2005247301B2 (en) 2004-04-16 2005-04-15 FCγRIIB-specific antibodies and methods of use thereof
MXPA06011796A MXPA06011796A (en) 2004-04-16 2005-04-15 FCgammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF.
CA002563314A CA2563314A1 (en) 2004-04-16 2005-04-15 Fcyriib-specific antibodies and methods of use thereof
EP05778285A EP1747237A4 (en) 2004-04-16 2005-04-15 Fc gamma riib-specific antibodies and methods of use thereof
IL178593A IL178593A (en) 2004-04-16 2006-10-15 Fcγriib-specific antibodies and methods of use thereof

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US56280404P 2004-04-16 2004-04-16
US60/562,804 2004-04-16
US58204404P 2004-06-21 2004-06-21
US58204504P 2004-06-21 2004-06-21
US60/582,044 2004-06-21
US60/582,045 2004-06-21
US65471305P 2005-02-18 2005-02-18
US60/654,713 2005-02-18

Publications (3)

Publication Number Publication Date
WO2005115452A2 WO2005115452A2 (en) 2005-12-08
WO2005115452A9 WO2005115452A9 (en) 2006-04-06
WO2005115452A3 true WO2005115452A3 (en) 2006-05-26

Family

ID=35451410

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/012798 WO2005115452A2 (en) 2004-04-16 2005-04-15 Fcϝriib-specific antibodies and methods of use thereof

Country Status (10)

Country Link
US (1) US20050260213A1 (en)
EP (1) EP1747237A4 (en)
JP (1) JP5367982B2 (en)
KR (1) KR20070038453A (en)
AU (1) AU2005247301B2 (en)
CA (1) CA2563314A1 (en)
IL (1) IL178593A (en)
MX (1) MXPA06011796A (en)
SG (1) SG173322A1 (en)
WO (1) WO2005115452A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845795B2 (en) 2014-06-27 2023-12-19 Innate Pharma NKp46 binding proteins

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) * 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8193318B2 (en) * 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) * 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8044180B2 (en) * 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
CA2495251C (en) * 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
WO2007094776A1 (en) * 2006-02-15 2007-08-23 William Marsh Rice University Compositions and methods for suppressing fibrocyte differentiation
US8012472B2 (en) 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
EP2017617A1 (en) 2002-12-23 2009-01-21 William Marsh Rice Univeristy Wound dressing
US7960512B2 (en) * 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004204494B2 (en) * 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2536408A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US7687265B2 (en) * 2003-11-25 2010-03-30 The General Hospital Corporation Foxn1 and pigmentation
US7521542B2 (en) * 2004-05-10 2009-04-21 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
US8647625B2 (en) 2004-07-26 2014-02-11 Biogen Idec Ma Inc. Anti-CD154 antibodies
CA2577405A1 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Anti-fc-gamma riib receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
EP2325207B1 (en) * 2004-11-12 2017-03-15 Xencor, Inc. FC variants with altered binding to FCRN
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CA2590935C (en) * 2004-12-15 2014-09-30 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
EP1674479A1 (en) * 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulation of Fc Gamma receptors for optimizing immunotherapy
WO2006073921A2 (en) * 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function
WO2006110593A2 (en) * 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2707152T3 (en) 2005-04-15 2019-04-02 Macrogenics Inc Covalent diabodies and uses thereof
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
DK2573114T3 (en) 2005-08-10 2016-07-04 Macrogenics Inc The identification and production of antibodies with variant Fc regions, and methods of using same
KR20080079301A (en) * 2005-12-09 2008-08-29 시애틀 지네틱스, 인크. Methods of using cd40 binding agents
JP2009520468A (en) * 2005-12-23 2009-05-28 ヴィヴェンティア バイオテック インコーポレーティッド Fusion protein library production and screening methods, and uses thereof
CA2644903A1 (en) * 2006-03-10 2007-09-20 Macrogenics, Inc. Identification and engineering of antibodies with variant heavy chains and methods of using same
EP4342995A2 (en) 2006-03-31 2024-03-27 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP2021029B1 (en) * 2006-05-26 2014-06-11 MacroGenics, Inc. Humanized fc gamma riib-specific antibodies and methods of use thereof
EP2032159B1 (en) * 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
ES2599319T3 (en) * 2006-06-26 2017-02-01 Macrogenics, Inc. Fc RIIB specific antibodies and their methods of use
EP2073843A4 (en) * 2006-09-15 2010-07-28 Sloan Kettering Inst Cancer Methods of diagnosing, treating, or preventing plasma cell disorders
US20080112961A1 (en) * 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
JP5220025B2 (en) 2006-12-04 2013-06-26 プロメディオール， インコーポレイテッド Combination therapy to treat fibrotic diseases
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
EP3424951A1 (en) 2007-06-21 2019-01-09 MacroGenics, Inc. Covalent diabodies and uses thereof
US8497243B2 (en) 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US20090176654A1 (en) 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
KR101397554B1 (en) * 2007-11-09 2014-05-21 재단법인서울대학교산학협력재단 Compositions and method for the diagnosis, prevention and treatment of Alzheimer's disease
US8795667B2 (en) * 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
HUE024903T2 (en) 2007-12-26 2016-02-29 Xencor Inc Fc variants with altered binding to fcrn
US8802093B2 (en) 2008-04-02 2014-08-12 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using same
EP3045475B1 (en) 2008-04-02 2017-10-04 MacroGenics, Inc. Bcr-complex-specific antibodies and methods of using same
KR102269708B1 (en) 2008-04-11 2021-06-25 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CA2726845C (en) 2008-06-04 2017-09-26 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
JP5734201B2 (en) 2008-12-19 2015-06-17 マクロジェニクス，インコーポレーテッド Covalently bonded diabody and use thereof
US10702583B2 (en) 2009-03-11 2020-07-07 Promedior, Inc. Treatment methods for autoimmune disorders
WO2010104959A1 (en) 2009-03-11 2010-09-16 Promedior, Inc. Treatment and diagnostic methods for hypersensitive disorders
KR20120057563A (en) * 2009-03-31 2012-06-05 노파르티스 아게 Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
ES2552793T3 (en) 2009-06-17 2015-12-02 Promedior Inc. SAP variants and their use
TW201110973A (en) * 2009-06-25 2011-04-01 Shiseido Co Ltd Methods for screening for anti-graying agents on the basis of AFF-4
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP5898082B2 (en) 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド Fc region-containing polypeptide exhibiting improved effector function by changing the degree of fucosylation and use thereof
WO2011108502A1 (en) * 2010-03-02 2011-09-09 協和発酵キリン株式会社 Modified antibody composition
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
PE20130479A1 (en) 2010-03-04 2013-05-12 Macrogenics Inc ANTIBODIES REACTIVE WITH B7-H3, IMMULOGICALLY ACTIVE FRAGMENTS OF THE SAME AND USES OF THE SAME
CN103154025B (en) 2010-08-02 2015-07-01 宏观基因有限公司 Covalent diabodies and uses thereof
GB201013989D0 (en) * 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
AU2011337704B2 (en) 2010-11-30 2017-06-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2012074097A1 (en) * 2010-12-03 2012-06-07 協和発酵キリン株式会社 Anti-cd33 antibody
KR102147548B1 (en) * 2011-02-25 2020-08-24 추가이 세이야쿠 가부시키가이샤 FcγRIIb-specific Fc antibody
EP3825325A3 (en) * 2011-03-30 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
MX347818B (en) 2011-05-21 2017-05-15 Macrogenics Inc Deimmunized serum-binding domains and their use for extending serum half-life.
SI2714733T1 (en) 2011-05-21 2019-06-28 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
CN103827300A (en) 2011-06-30 2014-05-28 中外制药株式会社 Heterodimerized polypeptide
TW201817744A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
CN113416256A (en) 2011-11-30 2021-09-21 中外制药株式会社 Drug comprising transporter (carrier) that enters into cell to form immune complex
TW202015731A (en) * 2012-02-24 2020-05-01 日商中外製藥股份有限公司 Antigen-Binding Molecule for Promoting Disappearance of Antigen via Fc[gamma]RIIB
MX2014014678A (en) 2012-05-30 2015-02-10 Chugai Pharmaceutical Co Ltd Target-tissue-specific antigen-binding molecule.
WO2013187495A1 (en) 2012-06-14 2013-12-19 中外製薬株式会社 ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION
TWI717591B (en) 2012-08-24 2021-02-01 日商中外製藥股份有限公司 Fcγ riib-specific fc region variant
JP6433297B2 (en) 2012-12-27 2018-12-05 中外製薬株式会社 Heterodimerized polypeptide
EP2956482B1 (en) 2013-02-14 2017-06-28 Innate Pharma Treatment of peripheral t cell lymphoma
CA2899241C (en) 2013-02-20 2023-03-28 Innate Pharma A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US9908938B2 (en) 2013-03-14 2018-03-06 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
KR20210130260A (en) 2013-04-02 2021-10-29 추가이 세이야쿠 가부시키가이샤 Fc region variant
UA116479C2 (en) 2013-08-09 2018-03-26 Макродженікс, Інк. Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2837637A1 (en) * 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
KR20220142539A (en) 2013-12-04 2022-10-21 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
SG11201606789SA (en) 2014-03-14 2016-09-29 Innate Pharma Humanized antibodies with increased stability
CA2952532A1 (en) 2014-06-27 2015-12-30 Innate Pharma Multispecific antigen binding proteins
CN106795223B (en) * 2014-08-13 2021-05-04 苏伯利莫尔公司 Antibodies to Fc gamma receptors IIB and Fc epsilon receptors
WO2016030488A1 (en) 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease
SG11201702544WA (en) 2014-09-29 2017-04-27 Univ Duke Bispecific molecules comprising an hiv-1 envelope targeting arm
US10329348B2 (en) 2014-10-23 2019-06-25 Innate Pharma Treatment of cancers using anti-NKG2A agents
MA41294A (en) 2014-12-19 2017-11-08 Chugai Pharmaceutical Co Ltd ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING FC REGION VARIANTS, AND METHODS OF USE
CN114773470A (en) 2015-02-05 2022-07-22 中外制药株式会社 Antibodies comprising an ion concentration-dependent antigen-binding domain, FC region variants, IL-8-binding antibodies and uses thereof
EP3270965B1 (en) * 2015-03-18 2020-05-06 Seattle Genetics, Inc. Cd48 antibodies and conjugates thereof
CA2990518A1 (en) 2015-06-23 2016-12-29 Innate Pharma Multispecific nk engager proteins
AU2016284866B2 (en) 2015-06-23 2022-09-29 Innate Pharma Multispecific antigen binding proteins
JP7141336B2 (en) 2015-12-25 2022-09-22 中外製薬株式会社 Anti-myostatin antibodies and methods of use
EP3430047A1 (en) 2016-03-15 2019-01-23 Innate Pharma Anti-mica antibodies
IL262396B2 (en) 2016-04-15 2023-09-01 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
CN116271014A (en) 2016-08-05 2023-06-23 中外制药株式会社 Compositions for preventing or treating IL-8 related diseases
CA3037851A1 (en) 2016-10-21 2018-04-26 Innate Pharma Treatment with anti-kir3dl2 agents
US20190322767A1 (en) 2016-12-23 2019-10-24 Innate Pharma Heterodimeric antigen binding proteins
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
WO2019011918A1 (en) 2017-07-10 2019-01-17 International - Drug - Development - Biotech Treatment of b cell malignancies using afucosylated pro-apoptotic anti-cd19 antibodies in combination with anti cd20 antibodies or chemotherapeutics
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
EP3713959A1 (en) 2017-11-21 2020-09-30 Innate Pharma Multispecific antigen binding proteins
WO2020152081A1 (en) 2019-01-22 2020-07-30 Innate Pharma Treatment of t cell lymphoma
AU2022246048A1 (en) 2021-03-26 2023-08-31 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
AU2022288123A1 (en) 2021-06-09 2023-11-30 Innate Pharma Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
CN117529504A (en) 2021-06-09 2024-02-06 先天制药公司 Multispecific antibodies that bind to CD20, NKP46, CD16 and are conjugated to IL-2

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
WO1988007089A1 (en) * 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP0359096B1 (en) * 1988-09-15 1997-11-05 The Trustees Of Columbia University In The City Of New York Antibodies having modified carbohydrate content and methods of preparation and use
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
WO1995013090A1 (en) * 1993-11-10 1995-05-18 Enzon, Inc. Improved interferon polymer conjugates
US6132764A (en) * 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6410690B1 (en) * 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6339069B1 (en) * 1996-10-15 2002-01-15 Elan Pharmaceuticalstechnologies, Inc. Peptide-lipid conjugates, liposomes and lipsomal drug delivery
ATE427966T1 (en) * 1997-02-11 2009-04-15 Immunomedics Inc STIMULATION OF AN IMMUNE RESPONSE THROUGH ANTIBODIES LABELED WITH THE ALPHA-GALACTOSYLE PITOPOPE
CA2248971A1 (en) * 1997-10-31 1999-04-30 Kyowa Hakko Kogyo Co., Ltd. .beta.1, 3-n-acetylglucosaminyltransferase, dna encoding it and its use
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7416726B2 (en) * 2000-04-13 2008-08-26 The Rockefeller University Enhancement of antibody-mediated immune responses
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2495251C (en) * 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
AU2004204494B2 (en) * 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7521542B2 (en) * 2004-05-10 2009-04-21 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
CA2577405A1 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Anti-fc-gamma riib receptor antibody and uses therefor
CA2590935C (en) * 2004-12-15 2014-09-30 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BORUCHOV AM AND YOUNG JW.: "Expression and modulation of the inhibitory Fcgamma receptor FcgammaRIIb (CD32b), on human dendritic cells (DCs)'", BLOOD., vol. 102, no. 11, 16 November 2003 (2003-11-16), XP009046819 *
REFF M E AND HEARD C.: "A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications.", CRIT REV ONCOL HEMATOL., vol. 40, no. 1, 2001, pages 25 - 35, XP002329383 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845795B2 (en) 2014-06-27 2023-12-19 Innate Pharma NKp46 binding proteins

Also Published As

Publication number Publication date
WO2005115452A9 (en) 2006-04-06
JP5367982B2 (en) 2013-12-11
MXPA06011796A (en) 2007-05-07
US20050260213A1 (en) 2005-11-24
KR20070038453A (en) 2007-04-10
EP1747237A2 (en) 2007-01-31
CA2563314A1 (en) 2005-12-08
JP2007532139A (en) 2007-11-15
IL178593A0 (en) 2007-02-11
EP1747237A4 (en) 2008-05-21
AU2005247301B2 (en) 2011-08-18
AU2005247301A1 (en) 2005-12-08
IL178593A (en) 2016-04-21
SG173322A1 (en) 2011-08-29
WO2005115452A2 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
WO2005115452A3 (en) Fcϝriib-specific antibodies and methods of use thereof
WO2008019199A8 (en) FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
WO2005110474A3 (en) HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
WO2004016750A3 (en) FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
WO2008105886A3 (en) HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
WO2006077471A3 (en) Combining therapies targeting multiple toll-like receptors and use thereof
WO2013071068A3 (en) Treatment of hematologic malignancies with an anti-cxcr4 antibody
EA200800355A1 (en) NEUTRALIZING HUMAN ANTIBODIES AGAINST B7RP1
WO2005103081A3 (en) Human monoclonal antibodies against cd20
WO2004014292A3 (en) EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
WO2005102387A3 (en) Therapeutic use of anti-cs1 antibodies
UA90457C2 (en) Human monoclonal antibody that specifically binds to human m-csf
WO2006138729A3 (en) Receptor antagonists for treatment of metastatic bone cancer
WO2008156713A3 (en) Anti-cd20 therapeutic compositions and methods
WO2008002933A3 (en) Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
WO2004100898A3 (en) Therapeutic use of anti-cs1 antibodies
UA93201C2 (en) Antibody neutralizing human tgf beta 1
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
WO2006053049A3 (en) Herbal composition phy906 and its use in chemotherapy
WO2005051307A3 (en) Epha2 agonistic monoclonal antibodies and methods of use thereof
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer
GEP20135826B (en) Novel antibodies used to treat cancer
WO2008100563A3 (en) Compositions and methods for diagnosing and treating cancer
WO2008118733A3 (en) Methods of treating cancer by administering human il-18 combinations
WO2005011605A3 (en) Combination therapies for multiple sclerosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/51-51/51, DRAWINGS, REPLACED BY NEW PAGES 1/51-51/51; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/011796

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007508555

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 178593

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2563314

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005247301

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020067023937

Country of ref document: KR

Ref document number: 2005778285

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005247301

Country of ref document: AU

Date of ref document: 20050415

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 4227/CHENP/2006

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2005247301

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580019962.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005778285

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067023937

Country of ref document: KR